Recce Pharmaceuticals Ltd
ASX:RCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Recce Pharmaceuticals Ltd
Revenue
Recce Pharmaceuticals Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Revenue
AU$1.1m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$413m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$76.8m
|
CAGR 3-Years
69%
|
CAGR 5-Years
145%
|
CAGR 10-Years
44%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$93.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Nyrada Inc
ASX:NYR
|
Revenue
AU$2.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
Glance View
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.
See Also
What is Recce Pharmaceuticals Ltd's Revenue?
Revenue
1.1m
AUD
Based on the financial report for Dec 31, 2025, Recce Pharmaceuticals Ltd's Revenue amounts to 1.1m AUD.
What is Recce Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
7%
Over the last year, the Revenue growth was -88%. The average annual Revenue growth rates for Recce Pharmaceuticals Ltd have been -29% over the past three years , 7% over the past five years .
